Neoadjuvant therapy to reduce tumor size and preserve tissue
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
For most basal cell carcinomas (BCCs), surgery comes first and is often the only treatment needed. But when a tumor is very large, sits next to the eye or nose, or has wrapped around important structures, removing it outright could mean losing an eyelid, part of the nose, or another feature that is hard to rebuild.
In these situations, doctors sometimes give medication before surgery to shrink the tumor first. This is called neoadjuvant therapy. This article explains when it is used for BCC, which drugs are involved, what the research shows, and the trade-offs to weigh.
Neoadjuvant therapy is treatment given before the main treatment — here, medication before surgery. The goal is not to replace the operation but to make it smaller and safer:
After the medication course, the surgeon removes what remains of the tumor and a pathologist checks the edges of the sample to confirm the cancer is fully out.
Vismodegib (brand name Erivedge) is an oralhedgehog pathway inhibitor. It blocks the signaling pathway that drives the growth of almost all BCCs, and it is the drug with the most published experience as neoadjuvant treatment. Sonidegib, a closely related hedgehog inhibitor, is sometimes used the same way.
The PD-1 inhibitorcemiplimabis approved for advanced BCC after hedgehog inhibitors, and giving it before surgery is an active area of study. For BCC this remains investigational and is generally available only through aclinical trial.
Neoadjuvant use of vismodegib is recognized in national treatment guidelines, but it is not a separate FDA-approved indication. Insurance coverage varies, and your team may need to document why it is the best choice for your tumor.
Neoadjuvant therapy is not for routine BCC. It is weighed when up-front surgery would be disfiguring or dangerous:
Periocular tumors where removing enough tissue could threaten the eyelid, tear drainage, or the eye itself.
Large nasal tumors where excision would remove cartilage or a substantial part of the nose.
Growths several centimeters across, or fixed to deeper tissue, where the planned defect is extensive.
Tumors that have already come back after one or more operations in the same area.
The plan is made together by thesurgeon (often a Mohs or oculoplastic surgeon), a medical oncologist, and sometimes a radiation oncologist, so everyone agrees on the goal before the drug starts.
In this phase 2 study of 55 patients with locally advanced BCC of the face, about 80% had their planned operation downstaged to a smaller procedure after roughly six months of vismodegib, and about a quarter had a complete response with no tumor left on biopsy.
A U.S. open-label trial found that three to six months of vismodegib before surgery reduced the final surgical defect area by roughly a third compared with the pre-treatment tumor size in high-risk BCC.
Case series of vismodegib before surgery for advanced BCC around the eye report that many patients kept the eye and avoided the more extensive removal that would otherwise have been required.
Overall, the evidence is from small trials and series rather than large randomized studies, but it consistently shows meaningful shrinkage and less extensive surgery for carefully selected tumors.
For a select group of large or delicately located basal cell carcinomas, a few months of the hedgehog inhibitor vismodegib before surgery can meaningfully shrink the tumor, leading to a smaller operation and better preservation of the eye, nose, or other structures.
It is not a way to avoid surgery, and it carries real side effects. Whether it makes sense depends on your specific tumor and goals — a decision best made with a surgical and medical oncology team experienced in advanced BCC.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for information about advanced basal cell carcinoma treatment
Chat with the Navigator